Upcoming Conferences for Tenaya Therapeutics
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a pioneering biotechnology company focused on developing transformative therapies for heart disease, is gearing up for significant investor conferences. These events represent a prime opportunity for the company to showcase its innovative research and advancements in genetic therapies aimed at treating critical heart conditions.
Conference Details
TD Cowen's Annual Health Care Conference
On March 4, Tenaya's CEO, Faraz Ali, will present at the TD Cowen’s Annual Health Care Conference. The presentation is scheduled for 1:10 PM to 1:40 PM ET and promises to highlight Tenaya’s groundbreaking work in the field of cardiovascular health.
Leerink Partners Global Healthcare Conference 2025
The following week, on March 12, Tenaya will also participate in the Leerink Partners Global Healthcare Conference. This event will feature a fireside chat format, allowing for an engaging dialogue about the company’s strategic direction and its ongoing projects. The chat is set for 8:40 AM to 9:10 AM ET, and it aims to provide insights into Tenaya's pipeline and future plans.
Accessing Conference Content
For those unable to attend the live presentations, a replay will be available on the company's website for around 30 days after each conference. Investors and interested parties can check the Investors section of the Tenaya website for access to these important discussions.
Innovative Solutions from Tenaya Therapeutics
Tenaya Therapeutics is on a mission to tackle heart disease by developing innovative therapies that address its fundamental causes. The company employs a unique approach that integrates various capabilities, including target validation and advanced manufacturing techniques. Their diverse portfolio consists of several promising treatments, such as:
- TN-201: A gene therapy designed for MYBPC3-related hypertrophic cardiomyopathy (HCM).
- TN-401: Aimed at treating PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
- TN-301: A small molecule HDAC6 inhibitor targeting heart failure with preserved ejection fraction (HFpEF).
Beyond these pipeline projects, Tenaya is developing several early-stage programs in preclinical trials, promising a comprehensive approach to heart disease treatment.
Ongoing Commitment to Innovation
As Tenaya Therapeutics continues its journey, the company is committed to delivering effective therapies for both rare genetic disorders and more common heart ailments. The commitment to innovation and improvement in patient outcomes is evident in their robust research and development efforts.
Contact Information
For further inquiries about Tenaya Therapeutics or their upcoming events, the following contacts are available:
Michelle Corral
VP, Corporate Communications and Investor Relations
Email: IR@tenayathera.com
Anne-Marie Fields
Precision AQ
Email: annemarie.fields@precisionaq.com
Frequently Asked Questions
What is the significance of Tenaya Therapeutics participating in investor conferences?
Participating in these conferences allows Tenaya to present its research, connect with investors, and showcase advancements in heart disease therapies.
When is Tenaya's presentation at the TD Cowen Annual Health Care Conference?
Tenaya's presentation is scheduled for March 4 from 1:10 PM ET to 1:40 PM ET.
How can investors access the webcasts from these conferences?
Investors can access the live and archived webcasts through the Investors section on Tenaya's website.
What innovative therapies is Tenaya currently working on?
Tenaya Therapeutics is focusing on gene therapies for various heart conditions, including TN-201 and TN-401, as well as small molecule inhibitors like TN-301.
Who can be contacted for more information about Tenaya Therapeutics?
Michelle Corral and Anne-Marie Fields are available for inquiries regarding corporate communications and investor relations.
